Gordon Van Slyke: A Trial Participant’s Inside Look at New Alzheimer’s Drug Leqembi

How new Alzheimer's drug Leqembi works, risks and who might benefitПодробнее

New Alzheimer's drug gets FDA approvalПодробнее

The New Alzheimer’s Drug: What is Leqembi?Подробнее

Gordon Van Slyke: A Trial Participant’s Inside Look at New Alzheimer’s Drug LeqembiПодробнее

Boston neurologist discusses new Alzheimer's drug LeqembiПодробнее

FDA fully approves Leqembi, first drug to slow progression of Alzheimer's diseaseПодробнее

FDA greenlights new Alzheimer's drug amid safety concernsПодробнее

Alzheimer’s drug Leqembi has full FDA approvalПодробнее

Lecanemab in Alzheimer’s Disease | NEJMПодробнее

Alzheimer's drug Leqembi receives full FDA approvalПодробнее

Potential breakthrough: New treatment for Alzheimer'sПодробнее

Walking Changes in Dementia #shortsПодробнее

Leqembi Alzheimer’s drug gets full FDA approvalПодробнее

FDA approvals new Alzheimer's drug.Подробнее

Experimental Alzheimer's drug shows benefits in phase 3 trialПодробнее

FDA Grants Approval for Alzheimer’s Drug Lecanemab | #MCAShortsПодробнее

Lecanemab: A Potential New Drug For Alzheimer's diseaseПодробнее

USC, UCLA among clinical trial team behind Leqembi, the first Alzheimer's to get full FDA approvalПодробнее

Clinical Trial Participant 'Biogen's Aducanumab Was Working' | Patient Perspectives | Being PatientПодробнее